CA3204495A1 - Substituted pyrazolo piperidine carboxylic acids - Google Patents
Substituted pyrazolo piperidine carboxylic acidsInfo
- Publication number
- CA3204495A1 CA3204495A1 CA3204495A CA3204495A CA3204495A1 CA 3204495 A1 CA3204495 A1 CA 3204495A1 CA 3204495 A CA3204495 A CA 3204495A CA 3204495 A CA3204495 A CA 3204495A CA 3204495 A1 CA3204495 A1 CA 3204495A1
- Authority
- CA
- Canada
- Prior art keywords
- compounds
- formula
- diseases
- salts
- preference
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20213020 | 2020-12-10 | ||
| EP20213020.9 | 2020-12-10 | ||
| PCT/EP2021/084987 WO2022122914A1 (en) | 2020-12-10 | 2021-12-09 | Substituted pyrazolo piperidine carboxylic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3204495A1 true CA3204495A1 (en) | 2022-06-16 |
Family
ID=73793025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3204495A Pending CA3204495A1 (en) | 2020-12-10 | 2021-12-09 | Substituted pyrazolo piperidine carboxylic acids |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20240051935A1 (https=) |
| EP (1) | EP4259617B1 (https=) |
| JP (1) | JP2023552583A (https=) |
| KR (1) | KR20230118144A (https=) |
| CN (1) | CN116710439A (https=) |
| AR (1) | AR124297A1 (https=) |
| AU (1) | AU2021393988A1 (https=) |
| CA (1) | CA3204495A1 (https=) |
| CL (1) | CL2023001632A1 (https=) |
| CO (1) | CO2023007335A2 (https=) |
| CR (1) | CR20230242A (https=) |
| DK (1) | DK4259617T3 (https=) |
| DO (1) | DOP2023000115A (https=) |
| EC (1) | ECSP23040828A (https=) |
| ES (1) | ES2997117T3 (https=) |
| FI (1) | FI4259617T3 (https=) |
| GE (2) | GEAP202316287A (https=) |
| HR (1) | HRP20241543T1 (https=) |
| HU (1) | HUE069255T2 (https=) |
| IL (1) | IL303296A (https=) |
| JO (1) | JOP20230132A1 (https=) |
| LT (1) | LT4259617T (https=) |
| MX (1) | MX2023006903A (https=) |
| PE (1) | PE20231501A1 (https=) |
| PL (1) | PL4259617T3 (https=) |
| PT (1) | PT4259617T (https=) |
| RS (1) | RS66294B1 (https=) |
| SA (1) | SA523441083B1 (https=) |
| SI (1) | SI4259617T1 (https=) |
| TW (1) | TW202237589A (https=) |
| WO (1) | WO2022122914A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4011873A1 (en) * | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
| EP4011874A1 (en) * | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
| EP4536205A1 (en) | 2022-06-09 | 2025-04-16 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
| JP2026504406A (ja) * | 2023-01-31 | 2026-02-05 | インビボサイエンシーズ インコーポレイテッド | 駆出率保持型心不全（ＨＦｐＥＦ）の治療に関するシステムおよび方法 |
| WO2025067414A1 (zh) * | 2023-09-27 | 2025-04-03 | 海思科医药集团股份有限公司 | 吡唑羧酸衍生物及其在医药上的应用 |
| WO2025162280A1 (zh) * | 2024-01-30 | 2025-08-07 | 海思科医药集团股份有限公司 | 吡唑羧酸衍生物及其在医药上的应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| KR20100059952A (ko) * | 2007-09-06 | 2010-06-04 | 머크 샤프 앤드 돔 코포레이션 | 가용성 구아닐레이트 사이클라제 활성제 |
| DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| EA023221B1 (ru) | 2010-02-27 | 2016-05-31 | Байер Интеллектуэль Проперти Гмбх | СВЯЗАННЫЕ БИС-АРИЛЬНЫЕ АРИЛ-ТРИАЗОЛОНЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ИХ ПРИМЕНЕНИЕ, ЛЕКАРСТВЕННОЕ СРЕДСТВО НА ИХ ОСНОВЕ И ДВОЙНОЙ АНТАГОНИСТ V1a/V2-РЕЦЕПТОРОВ |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| PE20130779A1 (es) | 2010-07-09 | 2013-06-21 | Bayer Ip Gmbh | Pirimidinas y triazinas condensadas y su uso |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| EP2632551B1 (en) * | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
| ES2748798T3 (es) * | 2012-09-07 | 2020-03-18 | Boehringer Ingelheim Int | Alcoxi pirazoles como activadores de la guanilato ciclasa soluble |
| WO2015095515A1 (en) * | 2013-12-20 | 2015-06-25 | Novartis Ag | Sgc activators for the treatment of glaucoma |
| UA121558C2 (uk) | 2014-11-03 | 2020-06-25 | Баєр Фарма Актіенгезеллшафт | Гідроксіалкілзаміщені фенілтриазольні похідні та їх застосування |
| GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
| JP7458683B2 (ja) * | 2020-12-10 | 2024-04-01 | バイエル・アクチエンゲゼルシヤフト | 眼科疾患の治療のためのｓＧＣ活性化剤の使用 |
| CN116829545A (zh) * | 2020-12-10 | 2023-09-29 | 拜耳公司 | 取代的吡唑基哌啶羧酸 |
-
2021
- 2021-12-09 EP EP21823605.7A patent/EP4259617B1/en active Active
- 2021-12-09 HU HUE21823605A patent/HUE069255T2/hu unknown
- 2021-12-09 PT PT218236057T patent/PT4259617T/pt unknown
- 2021-12-09 TW TW110146019A patent/TW202237589A/zh unknown
- 2021-12-09 JP JP2023535063A patent/JP2023552583A/ja active Pending
- 2021-12-09 ES ES21823605T patent/ES2997117T3/es active Active
- 2021-12-09 HR HRP20241543TT patent/HRP20241543T1/hr unknown
- 2021-12-09 US US18/256,647 patent/US20240051935A1/en active Pending
- 2021-12-09 CA CA3204495A patent/CA3204495A1/en active Pending
- 2021-12-09 MX MX2023006903A patent/MX2023006903A/es unknown
- 2021-12-09 WO PCT/EP2021/084987 patent/WO2022122914A1/en not_active Ceased
- 2021-12-09 DK DK21823605.7T patent/DK4259617T3/da active
- 2021-12-09 AU AU2021393988A patent/AU2021393988A1/en active Pending
- 2021-12-09 GE GEAP202316287A patent/GEAP202316287A/en unknown
- 2021-12-09 RS RS20241357A patent/RS66294B1/sr unknown
- 2021-12-09 PL PL21823605.7T patent/PL4259617T3/pl unknown
- 2021-12-09 PE PE2023001808A patent/PE20231501A1/es unknown
- 2021-12-09 SI SI202130234T patent/SI4259617T1/sl unknown
- 2021-12-09 CN CN202180081892.0A patent/CN116710439A/zh active Pending
- 2021-12-09 AR ARP210103422A patent/AR124297A1/es unknown
- 2021-12-09 LT LTEPPCT/EP2021/084987T patent/LT4259617T/lt unknown
- 2021-12-09 IL IL303296A patent/IL303296A/en unknown
- 2021-12-09 FI FIEP21823605.7T patent/FI4259617T3/fi active
- 2021-12-09 CR CR20230242A patent/CR20230242A/es unknown
- 2021-12-09 GE GEAP202116287A patent/GEP20247649B/en unknown
- 2021-12-09 KR KR1020237022818A patent/KR20230118144A/ko active Pending
-
2023
- 2023-06-01 EC ECSENADI202340828A patent/ECSP23040828A/es unknown
- 2023-06-02 CO CONC2023/0007335A patent/CO2023007335A2/es unknown
- 2023-06-06 CL CL2023001632A patent/CL2023001632A1/es unknown
- 2023-06-07 DO DO2023000115A patent/DOP2023000115A/es unknown
- 2023-06-07 SA SA523441083A patent/SA523441083B1/ar unknown
- 2023-06-08 JO JOJO/P/2023/0132A patent/JOP20230132A1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GEAP202316287A (en) | 2023-09-11 |
| ECSP23040828A (es) | 2023-07-31 |
| HUE069255T2 (hu) | 2025-02-28 |
| SI4259617T1 (sl) | 2025-02-28 |
| PL4259617T3 (pl) | 2025-03-17 |
| FI4259617T3 (fi) | 2024-11-27 |
| DK4259617T3 (da) | 2024-12-09 |
| CN116710439A (zh) | 2023-09-05 |
| SA523441083B1 (ar) | 2025-06-12 |
| JOP20230132A1 (ar) | 2023-06-08 |
| TW202237589A (zh) | 2022-10-01 |
| MX2023006903A (es) | 2023-06-26 |
| GEP20247649B (en) | 2024-07-25 |
| CL2023001632A1 (es) | 2023-11-10 |
| AU2021393988A1 (en) | 2023-06-22 |
| AU2021393988A9 (en) | 2024-09-19 |
| ES2997117T3 (en) | 2025-02-14 |
| CO2023007335A2 (es) | 2023-06-09 |
| CR20230242A (es) | 2023-07-19 |
| PT4259617T (pt) | 2024-12-05 |
| PE20231501A1 (es) | 2023-09-26 |
| IL303296A (en) | 2023-07-01 |
| AR124297A1 (es) | 2023-03-15 |
| JP2023552583A (ja) | 2023-12-18 |
| US20240051935A1 (en) | 2024-02-15 |
| LT4259617T (lt) | 2024-12-10 |
| EP4259617B1 (en) | 2024-10-23 |
| EP4259617A1 (en) | 2023-10-18 |
| RS66294B1 (sr) | 2025-01-31 |
| WO2022122914A1 (en) | 2022-06-16 |
| HRP20241543T1 (hr) | 2025-01-03 |
| KR20230118144A (ko) | 2023-08-10 |
| DOP2023000115A (es) | 2023-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12195448B2 (en) | Substituted pyrazolo piperidine carboxylic acids | |
| EP4259617B1 (en) | Substituted pyrazolo piperidine carboxylic acids | |
| EP4259618B1 (en) | Substituted pyrazolyl piperidine carboxylic acids | |
| EP4259616B1 (en) | Substituted pyrazolo piperidine carboxylic acids | |
| EA047635B1 (ru) | Замещенные пиразолопиперидинкарбоновые кислоты | |
| EA049460B1 (ru) | Замещенные пиразолопиперидинкарбоновые кислоты | |
| HK40073287A (en) | Substituted pyrazolo piperidine carboxylic acids | |
| HK40091213A (zh) | 取代的吡唑并哌啶羧酸 | |
| BR122025013946A2 (pt) | Ácidos carboxílicos de pirazolo piperidina substituídos, seus processos de preparação |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241120 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241120 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241120 |
|
| R15 | Change to inventor requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R15-R108 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRECT INVENTOR REQUEST RECEIVED Effective date: 20251002 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20251002 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251002 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251118 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251118 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251126 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251126 |
|
| R16 | Change to inventor recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R16-R110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRECT INVENTOR REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260121 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260121 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260122 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260122 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260122 |